GTx, Inc. Presents Preclinical Studies of GTx-758, a Selective Estrogen Receptor Alpha Agonist for First Line Treatment of Advanced Prostate Cancer, and GTx-230, an Orally Available Tubulin Antagonist for Cancer Refractory to Taxane and Vinca Alkaloid The

ATLANTA--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.